The American Cardiology College and American Heart Association (ACC/AHA) guidelines recommend mineralocorticoid receptor antagonists, like spironolactone, for patients with symptomatic HFrEF (Heidenreich et al. 2022), but the use case in heart failure with preserved ejection fraction (HFpEF) is less clear. The gene discussed is NR3C2; the disease is heart failure.